Agios Pharmaceuticals, Inc. AGIO R2KR3KPHARMA
Company Overview
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Dec 2025 Revenue of $54.03M (+48.0% YoY); net profit $-412.78M.
- Trailing 12 Months Year-on-year growth — revenue +259.3%, earnings -161.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.22% |
| 1 Year: | 259.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -161.27% |
Stock Price Performance
| 1 Year: | +1.07% |
| 6 Months: | +46.13% |
| 3 Months: | +0.08% |
| 1 Month: | +12.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.46 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AGIO Agios Pharmaceuticals, Inc. R2KR3KPHARMA | 37.00 | -5.28 | $2.21B | 0.00% | -38.86% | -34.34% | 7.22% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 11.36M | - | 8.76M | 40.41M | 15.20M | 30.01M | 30.23M | 26.22M | 26.02M | 35.44M | 87.10M | 37.35M | 34.71M | 44.05M | 0 | 0 | 0 | - | 832.00K | 5.58M | 3.52M | 5.61M | 6.71M | 7.40M | 8.19M | 8.62M | - | - | - | 12.46M | 12.88M | 19.97M | 20.75M | 44.74M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.70M | 1.68M | 1.88M | 1.32M | 3.00M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.75M | 11.20M | 18.09M | 19.43M | 41.75M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.81M | 128.07M | 139.67M | 129.45M | 152.30M |
| Operating Income | -23.59M | -56.47M | -63.51M | -57.41M | -67.05M | -84.60M | -79.02M | -90.13M | -94.01M | -72.95M | -99.16M | -96.36M | -97.48M | -113.86M | -109.06M | -105.93M | -87.03M | -83.26M | -80.29M | -92.43M | -91.22M | -91.22M | -91.15M | - | -101.14M | -97.64M | -91.09M | -90.61M | -93.70M | -100.90M | -92.07M | -105.82M | - | - | - | -127.06M | -116.87M | -121.58M | -110.03M | -110.55M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -125.80M | -115.50M | -120.31M | -108.66M | -109.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -112.02M | -103.43M | -109.06M | -99.11M | -100.70M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.12M | -8.88M | - | - | 0 | -1.02M | - | - |
| Net Income | -23.20M | -55.95M | -62.83M | -23.20M | -66.17M | -83.08M | -77.14M | - | -90.83M | -68.75M | -94.66M | - | -93.08M | -109.87M | -106.17M | - | -40.26M | -90.48M | -98.98M | - | 1.87B | -86.22M | -88.77M | - | -94.77M | -91.81M | -81.75M | -81.02M | -83.81M | -91.32M | -81.55M | -96.12M | - | - | - | -112.02M | -103.43M | -108.04M | -99.11M | -100.70M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.59 | -1.31 | -1.43 | -1.41 | 26.95 | -1.41 | -1.56 | -1.74 | -1.74 | -1.68 | -1.49 | -1.47 | -1.51 | -1.64 | -1.45 | -1.69 | 16.22 | - | -1.55 | -1.93 | -1.78 | - | -1.69 | -1.69 |
| R&D Expense | 44.04M | 50.80M | 60.64M | - | 62.73M | 79.82M | 72.92M | - | 78.22M | 86.73M | 82.56M | - | 95.58M | 107.39M | 101.67M | - | 55.36M | 54.09M | 51.94M | - | 57.67M | 62.01M | 64.00M | - | 70.12M | 74.52M | 64.97M | 67.30M | 68.89M | 81.84M | 68.62M | 77.40M | 72.45M | - | 72.74M | 91.94M | 86.80M | - | 81.15M | 100.75M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.84M | 25.11M | 25.55M | 65.36M | 59.12M | 69.89M | 43.01M | 94.39M | 117.91M | 0 | - | 14.24M | 26.82M | 36.50M | 54.03M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 1.70M | 2.88M | 4.17M | 6.34M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 12.54M | 23.94M | 32.33M | 47.68M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 401.58M | 415.43M | 458.07M | 519.82M |
| Operating Income | -16.63M | -23.00M | -38.88M | -54.13M | -118.70M | -200.99M | -320.79M | -362.48M | -316.27M | -335.92M | - | -389.05M | -391.49M | -425.74M | -472.13M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -380.48M | -384.86M | -420.08M | -466.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -231.80M | -352.09M | 717.97M | -413.80M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 44.24M | -1.02M |
| Net Income | -23.71M | -20.10M | -39.41M | -53.50M | -117.73M | -198.47M | -314.67M | -346.03M | -411.47M | -327.37M | - | -231.80M | -352.09M | 673.73M | -412.78M |
| Diluted EPS | - | - | - | - | - | - | - | - | -6.86 | -4.74 | - | -4.23 | -6.33 | 11.64 | -7.12 |
| R&D Expense | 31.25M | 41.04M | 54.50M | 100.37M | 141.83M | 220.16M | 292.68M | 341.32M | 214.26M | 220.81M | 256.97M | 279.91M | 295.53M | 301.29M | 339.54M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 137.01M | 201.21M | 491.90M | 420.06M | 619.09M | 614.40M | 858.46M | 890.74M | 852.95M | - | 1.24B | 937.12M | 1.66B | 1.30B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 832.77M | 833.84M | 965.60M | 942.05M |
| Cash & Equivalents | 77.88M | 117.66M | 91.30M | 71.56M | 14.03M | 71.76M | 160.75M | 102.72M | 70.50M | 80.93M | 127.44M | - | 139.26M | 88.20M | 76.25M | 89.13M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 8.49M | 19.08M | 27.62M | 32.92M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 2.21M | 2.81M | 4.11M | 10.58M |
| Total Liabilities | - | - | - | - | - | - | 260.50M | 238.89M | 170.92M | 250.21M | 453.45M | - | 137.90M | 126.10M | 122.24M | 104.11M |
| Current Liabilities | - | - | 35.11M | 36.93M | 61.09M | 52.89M | 88.43M | 94.94M | 93.50M | 92.89M | 94.39M | - | 62.63M | 67.95M | 81.16M | 82.21M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 85.66M | 72.00M | 56.99M | 40.21M |
| Total Equity | -29.59M | -52.78M | -72.02M | 131.48M | 424.37M | 345.12M | 358.59M | 375.50M | 687.54M | 640.53M | 399.50M | - | 1.10B | 811.02M | 1.54B | 1.19B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 71.26M | 72.16M | 73.37M | 74.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.22M | -49.55M | -56.40M | - | -76.95M | 38.56M | -285.23M | -304.42M | -370.62M | -290.76M | - | -309.48M | -296.06M | -389.84M | -372.98M |
| Investing Cash Flow | -22.36M | 23.04M | -87.22M | - | 128.31M | -119.35M | -57.91M | -273.82M | 91.44M | 75.75M | - | 243.26M | 239.57M | 363.44M | 377.18M |
| Financing Cash Flow | 77.36M | 142.00K | 123.88M | - | 6.37M | 169.78M | 285.11M | 546.02M | 289.61M | 261.52M | - | 2.35M | 5.43M | 14.44M | 8.68M |
| Capital Expenditure | -1.91M | -1.48M | -1.29M | -2.22M | -20.16M | -9.91M | -4.63M | -6.99M | -12.03M | -14.11M | - | -4.88M | -18.50M | -1.69M | -14.32M |
| Free Cash Flow | -17.12M | -51.02M | -57.69M | - | -97.11M | 28.65M | -289.86M | -311.41M | -382.65M | -304.87M | - | -314.36M | -314.56M | -391.53M | -387.29M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -63.87M | -51.05M | -11.96M | 12.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | 88.0% | 89.3% | 88.6% | 88.3% |
| Operating Margin % | -76.2% | -91.6% | -152.2% | -82.8% | -200.8% | -287.6% | -745.8% | -384.0% | -268.2% | - | - | -2,732.1% | -1,459.5% | -1,166.5% | -873.9% |
| Net Margin % | -108.6% | -80.1% | -154.2% | -81.9% | -199.1% | -284.0% | -731.6% | -366.6% | -349.0% | - | - | -1,627.8% | -1,312.6% | 1,845.9% | -764.0% |
| ROE % | 44.9% | 27.9% | -30.0% | -12.6% | -34.1% | -55.3% | -83.8% | -50.3% | -64.2% | -81.9% | - | -21.1% | -43.4% | 43.7% | -34.6% |
| ROCE % | - | -22.6% | -23.7% | -12.6% | -32.3% | -37.9% | -61.8% | -47.4% | -39.6% | -44.3% | - | -33.1% | -45.0% | -26.9% | -38.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.81% | 6.46M | $205.37M |
| 2 | Farallon Capital Management LLC | 9.91% | 5.92M | $188.23M |
| 3 | State Street Corporation | 5.92% | 3.53M | $112.40M |
| 4 | Lynx1 Capital Management Lp | 5.71% | 3.41M | $108.44M |
| 5 | Shaw D.E. & Co., Inc. | 5.20% | 3.11M | $98.83M |
| 6 | Vanguard Portfolio Management LLC | 4.85% | 2.90M | $92.19M |
| 7 | Vanguard Capital Management LLC | 4.49% | 2.68M | $85.31M |
| 8 | Armistice Capital, LLC | 4.02% | 2.40M | $76.34M |
| 9 | Erste Asset Management GmbH | 3.61% | 2.15M | $68.55M |
| 10 | Nomura Asset Management International Inc | 3.54% | 2.11M | $67.14M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AGIO
Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?
Agios Pharmaceuticals is pursuing US FDA accelerated approval for mitapivat in sickle cell disease after Priority Review of Phase 3 RISE UP data showing significant hemoglobin responses in patients aged 16 and older. The mixed RISE UP outco…
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare light-sensitivity disorder reported that its pivotal Phase 3 trial met…
FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings
Investors are set to turn their focus on FDA decisions on experimental treatments for hepatitis B, RRP, sickle cell disease and psoriatic arthritis.
4 High-Risk Stocks Built for Big Returns
These speculative investments could turbocharge a portfolio to market-beating returns.
Agios Pharmaceuticals (AGIO) Stock Looks Fully Priced Against Current Sales
Agios Pharmaceuticals has delivered a 37.6% gain over the past 3 years. The key question now is whether that share price aligns with the sales the business is generating. For anyone looking at Agios, the focus is less on recent swings and m…
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the com…
AGIO — Frequently Asked Questions
What is the current share price of Agios Pharmaceuticals, Inc. (AGIO)?
As of 2026-10-23 16:27 PDT, Agios Pharmaceuticals, Inc. (AGIO) trades at $37.00 on NasdaqGS. Its 52-week range is $22.34 to $45.49.
What is the market capitalisation of AGIO?
Agios Pharmaceuticals, Inc. (AGIO) has a market capitalisation of $2.21B on NasdaqGS.
What is the P/E ratio of AGIO?
AGIO trades at a trailing price-to-earnings (P/E) ratio of -5.28. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.85.
What is the return on equity (ROE) of AGIO?
AGIO has a return on equity (ROE) of -34.34%. Its return on capital employed (ROCE) is -38.86%.
Is AGIO a good stock to buy?
This page provides a data-driven analysis of Agios Pharmaceuticals, Inc. (AGIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.